Wednesday, October 24, 2018
DrugName : mifepristone
Corcept Therapeutics Incorporated, a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced that Judge Susan Wigenton of the United States District Court for the District of New Jersey has denied Teva Pharmaceuticals USA, Inc.’s motion to dismiss a lawsuit brought by Corcept alleging infringement of patents relating to the use of Korlym, Corcept’s medication for the treatment of patients with endogenous Cushing’s syndrome.
Corcept has sued Teva for infringement of two patents covering Korlym upon receipt of notice in February 2018 that Teva is seeking approval from the United States Food & Drug Administration to market a generic version of Korlym. In July 2018, Corcept filed an amended complaint asserting a third patent against Teva. Judge Wigenton’s denial of Teva’s motion means that Corcept’s lawsuit will proceed.
“We are gratified by today’s decision,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer, “and look forward to developing and presenting our case to the Court. We will vigorously enforce our intellectual property rights.”,
Key Facts
Intellectual Property
Legal And Regulatory
Other Product News
Product Development
There are a numerous viagra free shipping over here in the the web, just waiting for your access. If you want to use them, use natural ones and stay away from Propecia, as it causes many problems to the viagra soft tab http://appalachianmagazine.com/category/history/appalachian-history/page/2/ man who in turn puts him in a lot of trouble. However, the infertility achat cialis cipla caused by prostatitis has its way out. These are some levitra 20mg australia serious health conditions to blame for a man’s reduced quality of erection.
Teva Pharmaceuticals USA Inc and Corcept Therapeutics Inc
North America > United States of America